Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

被引:0
|
作者
Rubin, David T. [1 ]
Sands, Bruce E. [2 ]
Lichtenstein, Gary R. [3 ]
Baker, Thomas [4 ]
Huang, Kuan-Hsiang G. [4 ]
Germinaro, Matthew [4 ]
Miao, Ye [4 ]
Zhang, Hongyan [4 ]
Nancey, Stephane [5 ]
Allegretti, Jessica R. [6 ]
Feagan, Brian G. [7 ]
Hisamatsu, Tadakazu [8 ]
Panes, Julian [9 ]
Dignass, Axel [10 ]
Bressler, Brian [11 ]
Peyrin-Biroulet, Laurent [12 ,13 ]
机构
[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[2] Icahn Sch Med Mt Sinai, New York, NY USA
[3] Univ Penn, Philadelphia, PA USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Hosp Civils Lyon, Hop Lyon Sud, Pierre Benite, Auvergne, France
[6] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[7] Western Univ, London, ON, Canada
[8] Kyorin Univ, Sch Med, Tokyo, Japan
[9] Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, Ctr Invest Biomedica Red Enfermedades, Barcelona, Catalonia, Spain
[10] Goethe Univ, Agaples Markus Hosp, Frankfurt, Germany
[11] St Pauls Hosp, Vancouver, BC, Canada
[12] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France
[13] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
S903
引用
收藏
页码:S672 / S673
页数:2
相关论文
共 50 条
  • [1] Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
    Rubin, D.
    Sands, B.
    Lichtenstein, G.
    Baker, T.
    Huang, K. H.
    Germinaro, M.
    Miao, Y.
    Zhang, H.
    Nancey, S.
    Allegretti, J.
    Feagan, B.
    Hisamatsu, T.
    Panes, J.
    Dignass, A.
    Bressler, B.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1722 - I1723
  • [2] QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
    Peyrin-Biroulet, L.
    Rubin, D.
    Lichtenstein, G.
    Shipitofsky, N.
    Huang, K. H.
    Germinaro, M.
    Wilson, R.
    Zhang, H.
    DuVall, G. A.
    Cao, Q.
    Allegretti, J.
    Feagan, B.
    Hisamatsu, T.
    Panes, J.
    Dignass, A.
    Bressler, B.
    Sands, B.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 624 - 625
  • [3] QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
    Sands, Bruce E.
    Rubin, David T.
    Lichtenstein, Gary
    Shipitofsky, Nicole
    Huang, Kuan-Hsiang
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    DuVall, Aaron
    Cao, Qian
    Allegretti, Jessica R.
    Feagan, Brian G.
    Peyrin-Biroulet, Laurent
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Bressler, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S526 - S527
  • [4] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
    Allegretti, Jessica R.
    Peyrin-Biroulet, Laurent
    Feagan, Brian G.
    Bressler, Brian
    Lichtenstein, Gary R.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Shipitofsky, Nicole
    Jiang, Lingjing
    Zhang, Hongyan
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Sands, Bruce E.
    Rubin, David T.
    GASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572
  • [5] GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12
    Dignass, Axel
    Panes, Julian
    Rubin, David T.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Pandya, Dwiti
    Han, Chenglong
    Miao, Ye
    Zhang, Hongyan
    Gu, Fang
    Rowbotham, David S.
    Mihaly, Emese
    Bressler, Brian
    Lichtenstein, Gary R.
    Allegretti, Jessica R.
    GASTROENTEROLOGY, 2024, 166 (05) : S848 - S849
  • [6] Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12
    Dignass, A.
    Panes, J.
    Rubin, D. T.
    Huang, K. H. G.
    Germinaro, M.
    Pandya, D.
    Han, C.
    Miao, Y.
    Zhang, H.
    Gu, F.
    Rowbotham, D.
    Mihaly, E.
    Bressler, B.
    Lichtenstein, G. R.
    Allegretti, J. R.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I165 - I166
  • [7] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
    Allegretti, Jessica R.
    Rubin, David T.
    Bressler, Brian
    Huang, Kuan-Hsiang G.
    Shipitofsky, Nicole
    Germinaro, Matthew
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian
    Sandborn, William J.
    Sands, Bruce E.
    Hisamatsu, Tadakazu
    Lichi, Gary R.
    Lichtenstein, Gary R.
    Panes, Julian
    Dignass, Axel
    GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964
  • [8] Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
    Lichtenstein, Gary R.
    Dignass, Axel
    Rubin, David T.
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Miao, Ye
    Zhang, Hongyan
    Kierkus, Jaroslaw
    Seidler, Ursula
    Maemoto, Atsuo
    Allegretti, Jessica R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S623 - S624
  • [9] Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study
    Sridhar, S.
    Hart, A.
    Venkat, S.
    Huang, K. H. G.
    Yarandi, S.
    Germinaro, M.
    Vetter, M.
    Rubin, D. T.
    Dignass, A.
    Cua, D.
    Freeman, T.
    Waterworth, D.
    Mcrae, B.
    Verstockt, B.
    Branigan, P.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i422 - i422
  • [10] Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study
    Hisamatsu, Tadakazu
    Peyrin-Biroulet, Laurent
    Dignass, Axel
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Houck, Nicole
    Miao, Ye
    Zhang, Hongyan
    Argollo, Marjorie
    Takeuchi, Ken
    Filip, Rafal
    Allegretti, Jessica R.
    Feagan, Brian G.
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S810 - S810